AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06063954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.
Study NCT04918680 — intervention group
Intervention type: DEVICE
Intervention: EcoFit® Total Hip System with implacross® E Polyethylene
Description: The EcoFit® Total Hip System is a primary hip replacement system indicated for patients who are candidates for a primary cementless hip replacement. implacross® E Polyethylene is one of the components in the EcoFit® system.
Study NCT06026449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: After initial fase of habitual diet (6 months), patients will start Gluten-free diet for a period of 12 months
Study NCT05970848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Washing Pipe With a Spray Nozzle
Description: Administration of topical airway anesthesia via a washing pipe with a spray nozzle using the spray-as-you-go technique
Study NCT06647446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise supported by the digital physiotherapy and telerehabilitation software TRAK
Description: 8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software of digital physiotherapy and telerehabilitation TRAK. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
Study NCT06647446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard home-based exercise
Description: 8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
Study NCT06450522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist co-management of HF medication optimization
Description: In addition to usual care, participants with an initial Post-Discharge Medicine Clinic visit randomized to the intervention arm will receive pharmacist co-management of their medications, with the intent of to achieve rapid, maximum-tolerated pharmacotherapy for HFrEF as outlined by the 2021 CCS HF guidelines, and for HFmrEF/HFpEF as outlined by the 2022 ACC/AHA HF guidelines. This intervention will be delivered by a staff pharmacist at the St. Paul's Hospital, using the standard procedures outlined below:~For HFrEF: Where possible, a patient will be prescribed the combination of an ARNI, evidence-based beta-blocker, MRA, and SGLT2i at target HFrEF doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines.~For HFmrEF: We will target ACEI/ARB/ARNI+BB+MRA+SGLT2i. For HFpEF: We will target SGLT2i+MRA +/- ACEI/ARB/ARNI. The intervention will incorporate key components identified in a systematic review of observational studies of pharmacist-led optimization of HF.
Study NCT06450522 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study NCT06647693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Synchrony Games (MSG)
Description: The motor synchrony games (MSG) intervention uses fun but progressively more challenging gross motor and imitation games to promote behavioral self-regulation. Primary activities include: songs and fingerplays, stop and go games, and imitation games. These games get progressively more challenging over time by varying signal/modality. For example, going from a verbal and gestural paired stop and go signal to only a gestural stop signal. A fidelity checklist is used to ensure the intervention is appropriately used with the following criteria (uses >10 imitation trials, >10 Stop \& Go games, >3 trials/min on average with >5 trials/min preferred, use of progressive challenge, opportunities for Child Choice, environmental arrangement, and therapeutic strategies such as modeling).
Study NCT06006169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
Study NCT06006169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: SI-B003 was administered intravenously every 3 weeks (Q3W).
Study NCT06207656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBC
Description: Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice.
Study NCT06279468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intervertebral disc release
Description: After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. The intervertebral discs on the convex side of the scoliosis, situated between the vertebrae that have undergone Ponte osteotomy, will be approached and incised parallel to the intervertebral space. The intervertebral disc and endplate cartilage were incised and separated using reamers. Subsequently, the intervertebral space was expanded and irrigated, and the fragments of the intervertebral disc were extracted using nucleus pulposus forceps. Impacting bone graft into the intervertebral space, thus sustaining the optimal height of intervertebral space.
Study NCT06279468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ponte osteotomy
Description: After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. Subsequent corrective procedures can be performed immediately following Ponte osteotomy completion. The deformity was corrected using the bilateral rod rotation and segmental derotation technique after inserting rods. Under fluoroscopic guidance, compression, distraction, and in situ bending maneuvers were implemented as needed. Allograft bone material was utilized for the purpose of bone fusion
Study NCT05563961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panadol®
Description: Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
Study NCT05563961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SafeTynadol®
Description: Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)
Study NCT05628597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fos Biomedical patch product
Description: Participants will apply a Fos Biomedical patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
Study NCT05628597 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fos Biomedical patch product
Description: Participants will apply a Fos Biomedical patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
Study NCT05628597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fos Biomedical patch product:placebo
Description: Participants will apply a placebo patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
Study NCT05168995 — intervention group
Intervention type: DRUG
Intervention: BDP/FF NEXThaler® 100/6 micrograms
Description: BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)
Study NCT05393830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Restriction
Description: Three nights of sleep restricted to 4 hours per night.
Study NCT05628597 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fos Biomedical patch product:placebo
Description: Participants will apply a placebo patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
Study NCT06243510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apixaban
Description: Participants will be randomized to receive a prescription for prophylactic apixaban
Study NCT06243510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: Participants will be randomized to receive a prescription for prophylactic enoxaparin
Study NCT04855201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral
Study NCT04855201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT05180682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait Training
Description: the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training
Study NCT05180682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training
Study NCT06188715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 2 mg Oral Tablet
Description: Tablets of 2 mg moxidectin
Study NCT06188715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole
Study NCT06188715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole
Study NCT06188715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo MOX
Description: Placebo tablets for moxidectin
Study NCT06188715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MOX
Description: Placebo tablets for moxidectin
Study NCT06188715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ALB
Description: Placebo tablets for albendazole
Study NCT05044182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression and drainage seton
Description: Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
Study NCT05002946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-104
Description: single oral dose
Study NCT06206616 — intervention group
Intervention type: BEHAVIORAL
Intervention: Gluten-free diet
Description: Pediatric patients affected by newly diagnosed Celiac Disease (CD) according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will start a gluten-free diet (GFD), as normally expected for all CD patients. The assessment of adherence to the GFD will be carried out through the monthly compilation, by the children and/or their parents, of a specifically created and validated questionnaire.~Before and after the start of GFD enrolled patients will undergo an abdominal ultrasound to establish the presence and degree of hepatic steatosis.
Study NCT05002946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Hydrochloride 50Mg Oral Tablet
Description: single oral dose
Study NCT05887622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium chloride supplement
Description: Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
Study NCT05887622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
Study NCT05044182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cutting seton
Description: Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
Study NCT04769830 — intervention group
Intervention type: OTHER
Intervention: Bowel sound
Description: The characteristic data of bowel sounds, such as 24-hour average intestinal rate, duration of gastrointestinal sounds, amplitude, maximum frequency and average frequency, were collected to observe the differences of intestinal sounds among different AGI grades.
Study NCT05556122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intercostal nerve block
Description: General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
Study NCT05556122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lateral intercostal nerve block
Description: lateral intercostal nerve block
Study NCT05556122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine + compound betamethasone
Description: The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
Study NCT05556122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine + compound betamethasone
Description: The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
Study NCT04774510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography
Description: Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
Study NCT06411431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Chest Tube Removal
Description: Subjects within the Early Removal group will have their chest tube removed if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage
Study NCT06411431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chest Tube Removal
Description: Subjects within the Standard Removal group will have their chest tube removal on POD#2 if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage
Study NCT06411431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apical Chest Tube
Description: A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.
Study NCT06411431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apical Chest Tube
Description: A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.
Study NCT06519799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual hygiene products
Description: The influence on the intimate health of each product will be evaluated. As you can't not use a menstrual product during menstruation, no control group is included
Study NCT05744388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gliderite® shape modification
Description: The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
Study NCT06226064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VES001
Description: VES001 is an oral, blood brain barrier penetrating ligand of sortilin.
Study NCT06226064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
Study NCT06173674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: The music intervention will consist of three components including:~1. Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~2. Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~3. Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital.
Study NCT06098131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic
Description: Neurodynamic Slider and Tensioner Technique
Study NCT05418517 — intervention group
Intervention type: PROCEDURE
Intervention: Tracheostomy
Description: temporary tracheostomy insertion
Study NCT05418517 — intervention group
Intervention type: PROCEDURE
Intervention: Overnight intubation
Description: Patient who had overnight intubation
Study NCT05960591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADEPTH
Description: ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
Study NCT05043480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF
Description: Participants will receive pulsed electromagnetic fields (PEMF) exposure to alternate lower limbs weekly for 16 weeks. Participants will place alternate lower limb into the PEMF machine. Each lower limb will be exposed to 1.5mT magnetic field exposure for 10 mins once a week (total 10 min each week) for 16 weeks.
Study NCT06382818 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: COHORT A
Description: IMRT radiotherapy on whole breast according to the investigator's decision among:~* Moderate whole breast hypofractionated RT according to the START B schema with Fixed Field IMRT Technique: 40.05 Gy in 15 daily fractions over 3 weeks and a Sequential boost (+ 16 Gy/8 fr) or (+13.5/5 fr) if applicable.~* Extreme whole breast hypofractionated RT according to :~  * The FAST schema: Once-a-week ultra-HypoRT with Fixed Field IMRT Technique, 28.5 Gy in 5 fractions in 5 weeks~ * The FAST-Forward schema: Very accelerated course of HypoRT with Fixed Field IMRT Technique, 26 Gy in 5 fractions in 5 consecutive days
Study NCT06382818 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: COHORT B
Description: Breast radiotherapy according to the investigator's decision among:~* External partial VMAT: 40 Gy in 15 fractions to the partial breast only (tumorectomy bed).~* Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days.~* Whole Breast Normo fractionated IMRT with Fixed Field IMRT Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (60 Gy/25 fr) treatment for boost if applicable.
Study NCT06382818 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: COHORT C
Description: Whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol:~VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions).
Study NCT06382818 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: COHORT D
Description: Breast radiotherapy based on available clinical trials:~- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered.